[Form 4] Vir Biotechnology, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Vir Biotechnology, Inc. (VIR) disclosed that major shareholder and director-affiliated entity SVF Endurance (Cayman) Limited reported two open-market sales of Vir common stock. On 11/24/2025, it sold 227,803 shares at a weighted average price of $6.1491, and on 11/25/2025 it sold 235,971 shares at a weighted average price of $6.38. The sales were made under a Rule 10b5-1 trading plan entered into on September 3, 2025. After these transactions, the reporting person indirectly beneficially owned 14,110,209 Vir common shares, held of record by SVF Endurance (Cayman) Limited.

Insights

Equity Analyst

Director-affiliated fund sells a modest block of VIR under a Rule 10b5-1 plan, slightly reducing a still-large indirect position.

The filing shows **SVF Endurance (Cayman) Limited**, affiliated with **SoftBank Vision Fund (AIV M1) L.P.**, sold 227,803 and 235,971 shares of **Vir Biotechnology, Inc.** common stock on 11/24/2025 and 11/25/2025. The sales were coded "S" (open-market sales) and executed under a pre-established **Rule 10b5-1 trading plan** entered on 09/03/2025. After these trades, the reporting person still indirectly owns 14,110,209 shares, held of record by SVF Endurance (Cayman) Limited.

The average sale prices were $6.1491 and $6.38, each disclosed as weighted averages for multiple trades within price ranges of $5.93–$6.30 and $6.12–$6.6094. The sales are reported as **indirect** ownership changes, reflecting the fund structure where SB Investment Advisers (UK) Limited, as AIFM, manages SVF and controls acquisition and disposal decisions. This means the economic exposure is reduced, but the fund remains a large holder and director-related entity.

The key item to watch is whether similar 10b5-1 sales continue in future Form 4s, which would incrementally lower this holder's stake over time. The plan-based nature of the trades indicates a scheduled selling program rather than an ad hoc transaction, so follow-up filings over the coming quarters will show the pace and total size of this ongoing disposition.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SVF Endurance (Cayman) Ltd

(Last) (First) (Middle)

C/O WALKERS CORP LTD.,

190 ELGIN AVENUE

(Street)

GEORGE TOWN, E9 KY1-9008

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Vir Biotechnology, Inc. [ VIR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/24/2025		S(1)		227,803	D	$6.1491(2)	14,346,180	I	See footnote(3)
Common Stock	11/25/2025		S(1)		235,971	D	$6.38(4)	14,110,209	I	See footnote(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

SVF Endurance (Cayman) Ltd

(Last) (First) (Middle)

C/O WALKERS CORP LTD.,

190 ELGIN AVENUE

(Street)

GEORGE TOWN, E9 KY1-9008

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

SOFTBANK VISION FUND (AIV M1) L.P.

(Last) (First) (Middle)

1521 CONCORD PIKE

(Street)

WILMINGTON, DE 19803

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

SB INVESTMENT ADVISERS (UK) LTD

(Last) (First) (Middle)

69 GROSVENOR STREET

(Street)

LONDON, X0 W1K 3JP

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on September 3, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.93 to $6.30. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.12 to $6.6094. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	SVF Endurance (Cayman) Limited, By: /s/ Nilani Perera, Director	11/26/2025
	SoftBank Vision Fund (AIV M1) L.P., By: SB Investment Advisers (UK) Limited, its manager, By: /s/ Amanda Sanchez-Barry, General Counsel	11/26/2025
	SB Investment Advisers (UK) Limited, By: /s/ Amanda Sanchez-Barry, General Counsel	11/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did SVF Endurance (Cayman) Limited report in this Vir Biotechnology (VIR) Form 4?

SVF Endurance (Cayman) Limited reported two sales of Vir Biotechnology (VIR) common stock: 227,803 shares on 11/24/2025 and 235,971 shares on 11/25/2025, both in open-market transactions.

At what prices were the Vir Biotechnology (VIR) shares sold in this Form 4?

The 11/24/2025 sale had a weighted average price of $6.1491 per share, and the 11/25/2025 sale had a weighted average price of $6.38 per share, with each price reflecting multiple trades within stated ranges.

How many Vir Biotechnology (VIR) shares does the reporting person own after these transactions?

Following the reported transactions, the reporting person indirectly beneficially owned 14,110,209 shares of Vir Biotechnology common stock, held of record by SVF Endurance (Cayman) Limited.

Were the Vir Biotechnology (VIR) share sales under a Rule 10b5-1 trading plan?

Yes. The filing states that the sales were effected pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on September 3, 2025.

Who is the record holder of the Vir Biotechnology (VIR) shares reported in this Form 4?

SVF Endurance (Cayman) Limited is the record holder of the Vir Biotechnology common stock reported. It is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P..

Who manages SoftBank Vision Fund (AIV M1) L.P. in relation to these Vir (VIR) holdings?

SB Investment Advisers (UK) Limited has been appointed as alternative investment fund manager of SoftBank Vision Fund (AIV M1) L.P. and is exclusively responsible for making decisions related to the acquisition, structuring, financing, voting and disposal of its investments.